Simvastatin pretreatment enhances ischemia-induced neovascularization and blood flow recovery in streptozotocin-treated mice

Journal of Vascular Surgery
Po-Hsun HuangChun-Che Shih

Abstract

In contrast to statins, ezetimibe belongs to a new class of cholesterol-lowering agent not known to mediate pleiotropic effects. Here we investigate whether ezetimibe or simvastatin can help recover blood flow and reduce tissue damage after hindlimb ischemia surgery in diabetic mice. Diabetic mice were created by intraperitoneal streptozotocin injection in male FVB/NJ mice. All diabetic mice were subsequently divided into three groups: diabetic control, diabetic with simvastatin (0.2 mg/kg), and diabetic with ezetimibe (0.1 mg/kg). All experimental mice received hindlimb ischemia surgery after 2 weeks of drug treatment. Circulating endothelial progenitor cell number was determined by flow cytometry (Sca-1+/C-kit+/Flk-1+) in peripheral blood. In comparison to the mice in the diabetic control group (n = 6), wild-type mice (n = 6) and diabetic mice that received simvastatin (n = 6) had significantly increased ischemic/nonischemic limb blood perfusion ratio, higher capillary density (P < .05, respectively), and reduced ischemic limb damage (diabetic control, 80%; diabetic with simvastatin, 40%; diabetic with ezetimibe, 80%). However, these proangiogenic effects were not observed in diabetic mice that had been treated with ezetimibe...Continue Reading

References

Jan 19, 2000·Circulation·D J MaronM F Linton
Apr 13, 2000·The American Journal of Cardiology·D H WalterA M Zeiher
Oct 31, 2000·The American Journal of Cardiology·I S MalikK J Beatt
Jul 4, 2001·JAMA : the Journal of the American Medical Association·M A AlbertUNKNOWN PRINCE Investigators
Aug 8, 2001·The Journal of Clinical Investigation·J LlevadotT Asahara
Oct 20, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M SataR Nagai
Feb 13, 2002·Circulation·Michael WeisJohn P Cooke
Jan 24, 2003·Clinical Cardiology·Peter Libby, Masanori Aikawa
Feb 21, 2004·Science·Scott W AltmannMichael P Graziano
May 21, 2005·Circulation Research·Munekazu YamakuchiCharles J Lowenstein
Jun 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Margarita Garcia-CalvoNancy A Thornberry
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Aug 2, 2008·The New England Journal of Medicine·Daniel Steinberg
Jul 19, 2013·Journal of Clinical Medicine Research·Akshar Y PatelJames L Vacek
Mar 4, 2014·European Heart Journal·Dharam J KumbhaniUNKNOWN REACH Registry Investigators

❮ Previous
Next ❯

Citations

Mar 14, 2019·Contrast Media & Molecular Imaging·J L GoggiK K Bhakoo
Apr 2, 2019·Journal of Plastic Surgery and Hand Surgery·Dincer AltınelSevgi Kurt Yazar
Oct 15, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Qingsheng YinYanjun Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.